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Abstract
Objective—To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing 
regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus 
ritonavir-boosted darunavir in a single-arm, open-label, 96-week study.
Methods—24 antiretroviral-naïve R5 HIV-1-infected participants received maraviroc 150 mg 
and DRV/r 800/100 mg (MVC/DRV/r) once-daily. The primary outcome was virologic failure 
(VF) = confirmed viral load (VL) >50 copies/mL at week 24 in the modified intent-to-treat 
population. To determine viral dynamics, participant-specific first- and second-phase empirical 
Bayes estimates were compared to decay rates from efavirenz plus lopinavir/ritonavir, lopinavir/
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ritonavir plus 2NRTIs and efavirenz plus 2NRTIs. Maraviroc plasma concentrations were 
determined at weeks 2, 4,12, 24 and 48.
Results—Baseline median (Q1, Q3) CD4 count and VL were 455 (299, 607) cells/mm3 and 4.62 
(4.18, 4.80) log10 copies/mL, respectively. VF occurred in 3/24 participants (12.5 % [95% CI 2.7, 
32.4]) at week 24. One of these resuppressed, yielding a week 48 VF rate of 2/24 (8.3 % [95% CI 
1.0, 27.0]). The week 48 failures were 2 of the 4 (50%) participants with baseline VL >100,000 
copies/mL. Week 96 VF rate was 2/20 (10 % [95% CI 1.2, 31.7]). Phase 1 decay was faster with 
MVC/DRV/r than reported for ritonavir-boosted lopinavir plus 2 NRTIs (p=0.0063) and similar to 
efavirenz-based regimens. Individual maraviroc trough concentrations collected between 20–28 
hours post dose (n=59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled 
steady-state concentration was 128 ng/mL.
Conclusion—MVC/DRV/r 150/800/100 mg once-daily has potential for treatment-naïve 
patients with R5 HIV-1.
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INTRODUCTION
Although several nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens have 
been investigated for initial treatment of HIV [1–4], all recommended regimens worldwide 
include two NRTIs [5–9]. Effective NRTI-sparing regimens would provide options for 
individuals with transmitted NRTI resistance and renal impairment and avoid long-term 
NRTI toxicities [10]. Maraviroc (MVC) is a CCR5 receptor antagonist with activity against 
R5 HIV-1 [11], and possible though unproven immunomodulatory properties [12, 13]. 
Darunavir (DRV) is a protease inhibitor (PI) with a high barrier against resistance [14]. Both 
MVC and ritonavir-boosted DRV (DRV/r) have reliable cerebrospinal fluid penetration [15, 
16], rare serious toxicities [15, 17] and are associated with robust CD4+ T (CD4) cell 
reconstitution [18, 19].
The recommended MVC dose when combined with NRTIs is 300 mg twice-daily [5]. 
Among treatment-naïve patients randomized to MVC 300 mg plus lamivudine/zidovudine 
twice-daily in the MERIT study, the probability of virologic success decreased when 
average MVC plasma concentration (Cavg) and trough concentrations (Ctrough) fell below 75 
ng/mL and 25 ng/mL, respectively [20]. DRV/r inhibits cytochrome P450 (CYP) 3A4-
mediated metabolism of MVC, resulting in a four-fold increase in MVC area under the 
plasma concentration-time curve (AUC) [11, 21]. The recommended MVC dose when co-
administered with DRV/r is 150 mg twice-daily [5]. However, half of the recommended 
dose (150 mg once-daily) combined with DRV/r 800/100 mg daily produced median (IQR) 
MVC Ctrough of 43 (35–55) ng/mL in a clinical cohort [22]. In the MOTIVATE study, 
treatment-experienced patients were randomized to placebo, MVC 150 mg once-daily or 
MVC 150 mg twice-daily combined with an optimized background regimen that included 
several investigator chosen PIs but not darunavir [23]. At 48 weeks, plasma HIV-1 RNA 
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concentration (viral load, VL) was < 50 copies/mL in 179/414 (43%) and 194/426 (46%) of 
participants on daily versus twice-daily MVC, respectively.
We conducted the single-arm MaravIroc plus Darunavir/ritonavir Study (MIDAS) 
[clinicalTrials.gov Identifier: NCT00993148] to explore whether once-daily MVC 150 mg 
plus DRV/r 800/100 mg (MVC/DRV/r) is an active NRTI-sparing regimen for initial 
treatment of R5 HIV-1. We also evaluated the early HIV-1 decay and MVC 
pharmacokinetics (PK) of this novel regimen.
METHODS
Study participants
Participants were treatment-naïve HIV-1-infected patients who were at least 18 years old 
with: i) VL of 5,000 to 500,000 copies/mL within 90 days prior to study entry; ii) R5 virus 
by the enhanced sensitivity Trofile assay (Trofile ES); and iii) CD4 count > 100 cells/mm3. 
We excluded patients with active hepatitis B, protocol-specified abnormal laboratory values, 
or any DRV resistance-associated mutation (V11I, V32I, L33F, I47V, I50V, I54L, I54M, 
T74P, L76V, I84V and L89V). Each participant was invited to participate in a viral 
dynamics substudy. Ethics review committees at each research site approved the study. 
Participants were provided a written informed consent. An independent Monitoring 
Committee reviewed the study after the first 15 patients reached week 12.
Study intervention
Each participant received open-label DRV 800 mg (two 400 mg tablets), ritonavir 100 mg 
(one capsule) and MVC 150 mg (one tablet) co-administered once-daily with food.
Procedures and assessments
At the first screening visit, a Trofile ES assay on plasma was performed (Monogram, Inc., 
San Francisco, California, USA). Participants with R5 virus only returned for the second 
screening visit where other eligibility criteria were assessed. Study entry (day 0) occurred 
within 90 days of the first screening evaluation. Subsequent evaluations occurred at weeks 1, 
2, 4, 12, 24, 36 48, 60, 72, 84 and 96. VL was determined at entry and all subsequent 
evaluation time-points. Hematologic, liver function and blood chemistry tests were 
performed at entry and weeks 2, 4, 12, 24, 36, 48, 60, 72, 84 and 96. CD4 count was 
determined at entry and weeks 12, 24, 36, 48, 60, 72, 84 and 96. Fasting lipid levels were 
measured at entry and weeks 24, 48 and 96. Participants in the viral dynamics sub-study 
underwent additional VL determination on days 2, 4 and 10. Random samples for PK 
evaluation were collected and an adherence questionnaire was administered at weeks 2, 
4,12, 24 and 48. Participants were classified as perfectly adherent if they reported taking 
study medications with food and had no missed doses in the preceding 4 days [24]. 
Participants with suspected virologic failure (VF) returned within 7–35 days for a failure 
confirmation visit where adherence was assessed and samples collected for VL, protease 
genotype, Trofile ES, MVC phenotypic assay, CD4 count, and PK evaluation.
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VL was determined using the COBAS® AmpliPrep/COBAS® Taqman® HIV-1 assay 
(Roche). Resistance to PIs at the time of VF was assessed by genotyping the HIV-1 protease 
gene from plasma HIV-1 RNA. To isolate and sequence independent full-length env clones, 
viral RNA was extracted from patient plasma samples (QIAamp, Qiagen). Independent env 
gp160 amplicons were generated by nested PCR as previously described [25]. Tropism and 
MVC resistance testing were done at time of VF.
Maraviroc bioanalysis and pharmacokinetics
A validated protein precipitation method using acetonitrile (AcN) containing internal 
standard (MVC-d6) was employed to extract MVC from human plasma. An aliquot of the 
supernatant was further diluted with 0.5% trifluoroacetic acid to maintain signal intensity 
within the linear range of the instrument. Reversed phase chromatographic separation was 
performed on an XBridge™ C18 analytical column (2.1 × 50mm, 3.5mm) under isocratic 
conditions. A binary mobile phase consisting of 0.1% formic acid in water and 0.1% formic 
acid in acetonitrile (72:28) was used and provided adequate separation from other analytes 
in the assay. Detection and quantitation was achieved by multiple reaction monitoring 
(MRM), and MVC and internal standard (MVC-d6) were detected using the following 
transitions for protonated molecular products [M+H]+: m/z MVC 514.2 → 106.0; m/z 
MVC-d6 520.3 → 115.0. The dynamic range was 5 to 5,000 ng/mL using a 20 µL plasma 
sample. PK modeling was conducted using ADAPT 5 (Biomedical Simulations Resource, 
Los Angeles, CA). [26]. A two-compartment model was utilized and MVC absorption and 
clearance processes were assumed to be linear. Since few data points were available in the 
absorptive phase, the absorption rate constant (Ka) was fixed at 1.0 and no lag time was 
assessed. Covariates were not examined in this PK dataset.
Outcome measures
The primary outcome was VF (defined as confirmed plasma VL > 50 copies/mL) at week 
24. Secondary outcome measures were VF at weeks 48 and 96, change in CD4 count, 
adherence to study treatment, MVC PK, early viral decay, incidence of grade ≥3 or any 
grade if it led to drug discontinuation, change in viral tropism or emergence of protease or 
MVC resistance.
Statistical methods
With a sample size of 25 participants, assuming a 10% participant loss by week 24, if the 
observed VF rate was between 15% and 25%, then the 95% confidence interval (CI) would 
have a width of ±15% to ±18%. The 95% CI width was calculated using large sample 
approximation assuming a binomial distribution. Efficacy analysis was based on a modified 
intent-to-treat (ITT) population, which included all participants who initiated MVC/DRV/r 
and censored participants at time of loss to follow-up or treatment modification if the last 
VL was < 50 copies/mL. VL < 50 copies/mL while on MVC/DRV/r was considered a 
success. In secondary analysis, participants lost to follow up or who had any treatment 
modification were considered failures.
Viral decay rates were estimated with a bi-exponential nonlinear mixed effects model using 
VL at days 0, 2, 4, 7, 10, 14 and 28 after initiating MVC/DRV/r. Models were fit to the data 
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on a log10 scale to normalize the error distribution [27]. Participant-specific first- and 
second-phase empirical Bayes estimates were compared to decay rates from efavirenz (EFV) 
plus lopinavir/ritonavir (LPV/r), LPV/r plus 2NRTIs and EFV plus 2NRTIs arms of ACTG 
A5160s [28] and EFV plus 2NRTIs arm of ACTG A5166s [29] using the primary data. We 
used a 2-sided Wilcoxon rank sum test unadjusted for multiple comparisons (A5160s and 
A5166s decay curves were determined from data through week 8). Models were also fit 
through week 12 to investigate bias of decay estimates in comparison to A5160s and 
A5166s since week 8 VLs were not collected with MVC/DRV/r. Viral decay models 
through week 4 are reported to eliminate bias from censoring undetectable VL values (0% 
through week 4 vs. 27% through week 12).
RESULTS
Study Participants
A total of 46 antiretroviral naïve HIV-1-infected volunteers underwent screening at five U.S. 
research sites. Nine of these (20%) had non-R5 virus and 12 failed other eligibility criteria. 
Twenty-five participants with R5 HIV-1 enrolled in the study: median (Q1, Q3) age was 38 
(31, 43) years, 88% were male, and 60% were White non-Hispanic. Baseline median CD4 
count and VL were 455 (299, 607) cells/mm3 and 4.62 (4.18, 4.80) log10 copies/mL, 
respectively. VL was >100,000 copies/mL in 4 (16%) participants, 10,000–100,000 
copies/mL in 16 (64%) participants, and <10,000 copies/mL in 5 (20%). Baseline resistance 
mutations were detected in 5 (20%) participants: 1 had PI (D30N) plus NRTI (L210W, 
M41L, T215C) mutations; 3 had NNRTI (K103N, Y181C) mutations only and 1 had 
NNRTI (Y181C) plus NRTI (M41L, T215D) mutations.
Virologic response
One participant did not initiate MVC/DRV/r and was not included in the analysis. Twenty 
four participants initiated MVC/DRV/r All the participants with confirmed VL > 50 
copies/mL at or after week 24 are shown in Table 1. Participants A, B and D experienced 
VF at week 24; VF rate = 3/24 (12.5 % [95% CI 2.7, 32.4]). All these participants remained 
on MVC and one (Participant D) later resuppressed to VL <50 copies/mL. VF rate at week 
48 was 2/24 (8.3 % [95% CI 1.0, 27.0]). The week 48 failures were 2 of the 4 participants 
(50%) with baseline VL >100,000 copies/mL. All the 20 participants with baseline VL 
<100,000 copies/mL had VL <50 copies/mL at week 48. In secondary analysis considering 
participants lost to follow up or who had any treatment modification as failures, VF rates at 
weeks 24 and 48 remained unchanged because none of the 24 participants who initiated 
MVC/DRV/r was lost to follow up or had treatment modification through week 48.
To derive the week 96 VF rate, we censored 2 participants who were lost to follow up after 
week 48 (at week 72 and week 84, respectively) while their VLs were < 50 copies/mL on 
MVC/DRV/r (not shown in Table 1). In addition, we censored 2 other participants (A and C 
in Table 1) who switched from MVC/DRV/r while suppressed. Thus, the virologic failures 
at week 96 were Participants B and E in Table 1, yielding a VF rate of 2/20 (10 % [95% CI 
1.2, 31.7]). In secondary analysis considering participants lost to follow up or who had any 
treatment modification as failures, VF at week 96 was 6/24 (25 % [95% CI 9.7, 46.7]). All 
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the subjects with VF reported perfect adherence at that time point, except Patient E at week 
96.
CD4 response and safety
Median (Q1, Q3) CD4 count change from baseline was +247 (119, 340) cells/mm3 and +216 
(119, 346) cells/mm3 at weeks 48 and 96, respectively. The only grade 3 abnormality 
assessed as at least possibly related to the study regimen was LDL-cholesterol elevation in 
one participant. There were no grade 4 adverse events or study discontinuations due to 
adverse events.
Resistance
None of the participants with VF had any baseline resistance mutation. We limited Trofile 
ES, protease genotyping and phenotypic testing of MVC susceptibility to participants with 
VL > 200 copies/mL after week 48 (Patients A, B and E in Table 1). HIV-1 tropism 
remained R5 in the 2 samples that were successfully tested. Genotypic and phenotypic DRV 
and MVC resistance testing could not be performed because HIV-1 pol and envelop 
amplification failed with different amplification strategies in all tested samples most of 
which had too low plasma virus concentrations. To confirm RNA integrity, gag was 
successfully amplified from one of the two patients, suggesting that primer mismatch may 
also have played a role in our inability to amplify and sequence HIV-1 pol and envelope.
Viral dynamics
Fifteen participants enrolled in the viral dynamics sub-study with median (Q1,Q3) 
pretreatment VL of 4.6 (4.2,4.8) log10 copies/mL. As shown in Table 2, median phase 1 
decay was faster with MVC/DRV/r than reported for LPV/r plus 2 NRTIs [28]. The faster 
decay corresponded to a shorter median half-life (1.0 day vs. 1.3 days, respectively). The 
median phase 1 decay rate in this study was not significantly different from the phase 1 
decay rates reported for EFV plus LPV/r or EFV plus 2 NRTIs, respectively [28, 29]. 
Median phase 2 decay with MVC/DRV/r was slower than reported for EFV plus LPV/r, 
LPV/r plus 2NRTIs and EFV plus 2NRTIs, respectively in A5160s [28], and slower than the 
phase 2 decay rate reported for EFV plus 2 NRTIs in A5166s [29]. Population average 
(fixed effects) biexponential decay in VL is shown in Figure 1. Since VL was not collected 
at week 8 in the current study, a sensitivity analysis was conducted to determine if observed 
decay rates were affected by fitting a model to week 4. We found no significant differences 
between the first- and second-phase decay rates of models run through week 4 or through 
week 12 (p>0.7).
Median (Q1, Q3) transition time (the day and HIV-RNA level at which production of HIV-
RNA decay from short- and longer-lived cells is equal) was longer with MVC/DRV/r (13 
days (11,17)) compared to EFV plus LPV/r and EFV plus 2NRTIs in A5160s (12 days 
(11,13)) and EFV plus 2NRTIs in A5166s (11 days (10,13)). An earlier median transition 
time was observed when compared to the LPV/r plus 2NRTIs arm (14 days (12,19)). 
Median predicted VL at transition was higher for MVC/DRV/r compared to the two EFV 
plus 2NRTIs arms (2.79 log10 copies/mL vs. 2.65 and 2.78). Median predicted VL at 
Taiwo et al. Page 6






















transition was lower than EFV plus LPV/r and LPV/r plus 2NRTIs (2.93 and 2.95 log10 
copies/mL, respectively).
Pharmacokinetics
A total of 145 MVC plasma concentration-time points were collected. Of these, 59 fell 
within the 20–28 hour Ctrough collection window and 133 were used for modeling. From the 
raw data, the average peak (between 1–4 hours post dose) was 363 ng/mL and the average 
(± standard deviation) Ctrough (between 20–28 hours post dose) was 39.3 ± 22.8 ng/mL. 
Overall, individual Ctrough values ranged from 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 
ng/mL). A linear two-compartment model provided reasonable fits to the data (Figure 2). 
The modeled MVC clearance (CL/F) was 48 ± 8.4 L/h. Central distribution volume (Vc/F), 
intercompartmental clearance (CLd), and peripheral distribution volume (Vp/F) were 213±35 
L, 42.5±21.6 L/h, and 278±167 L, respectively. The median modeled AUC24 was 3073 
ng·h/mL and the steady-state concentration (Cavg) was 128 ng/mL. The population half-life 
(T1/2) was estimated to be 10.3±3.5 hours. The modeled MVC peak (Cmax at 2 hours post 
dose) and Ctrough (at 24 hours) concentrations were 415 and 36.1 ng/mL, respectively. VF 
was not explained by MVC plasma concentrations (Table 1).
DISCUSSION
The MIDAS study is the first to explore the virologic activity of the nucleos(t)ide-sparing 
regimen of MVC/DRV/r in treatment-naïve patients. Twenty-one of the twenty-four (87.5%) 
treatment-naïve participants treated with MVC/DRV/r 150/800/100 mg once-daily in this 
study had VL <50 copies/mL at week 24. At 48 weeks, VL was < 50 copies/mL in 22/24 
participants (92%). Notably, both participants with VL > 50 copies/mL at week 48 had 
pretreatment VL >100,000 copies/mL but one of them (Patient A in Table 1) achieved VL < 
50 copies/mL after almost two years on MVC/DRV/r. Virologic response to MVC/DRV/r 
was durable through week 96 with all but two participants (90%) maintaining viral 
suppression. CD4 counts increased by a median of 216 cells/mm3 from baseline to week 96. 
The regimen was well tolerated.
Of the NRTI-sparing regimens investigated in treatment-naïve patients to date, MVC 150 
mg plus atazanavir/ritonavir 300/100 mg (MVC/ATV/r) has the closest antiretroviral drug 
composition to MVC/DRV/r. In Study A4001078, 44 of 59 (74.6%) patients treated with 
MVC/ATV/r had VL < 50 copies/mL at week 48 [30], dropping to (40/59) 67.8% at week 
96 [30]. The corresponding suppression rates for atazanavir/ritonavir 300/100 mg plus fixed-
dose tenofovir/emtricitabine were 83.6% and 82.0%, respectively. Hyperbilirubinemia was 
more common with MVC/ATV/r. These results coupled with the relatively limited CNS 
penetration of atazanavir [31] have reduced enthusiasm for MVC/ATV/r. In the SPARTAN 
study, atazanavir 300 mg twice daily plus raltegravir 400 mg twice-daily was associated 
with high rates of raltegravir resistance during VF and treatment-limiting hyperbilirubinemia 
[3]. Similarly, LPV/r 400/100 mg twice-daily plus EFV 600 mg daily was associated with 
high rates of NNRTI resistance during VF [1]. We recently reported that, among patients 
with pretreatment VL >100,000 copies/mL, DRV/r 800/100 mg once-daily plus raltegravir 
400 mg twice-daily was associated with higher than expected rate of VF and a propensity for 
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raltegravir resistance during VF [4]. LPV/r plus raltegravir was non-inferior to LPV/r plus 
tenofovir/emtricitabine at week 96 (66.3% versus 68.6%, respectively), but the mean 
baseline VL was relatively low (4.25 log10 copies/mL) in that study [2]. No two-drug NRTI-
sparing regimen is currently recommended, although DRV/r plus raltegravir is being 
investigated further [ANRS 143; NCT01066962].
The average MVC Ctrough achieved with MVC/DRV/r 150/800/100 mg daily in MIDAS was 
39.3 ng/mL. Although Ctrough >25 ng/mL was associated with a higher probability of 
virologic response in MERIT [20], it was not determinative of success in our study. The two 
participants (A and B) with Ctrough measurements at VF had levels >25 ng/mL. Also, none 
of three participants who had Ctrough < 25 ng/mL at 50–100% of assessed time-points 
experienced VF (data not shown). The modeled MVC Cavg of 128 ng/mL in the current 
study exceeds the Cavg (75 ng/mL) associated with virologic response in MERIT. MVC Cavg 
may have a better prognostic measure of virologic response than the Ctrough [20]. Overall, 
our pharmacokinetic results are consistent with other studies that investigated once-daily 
dosing of 150 mg MVC with DRV/r 800/100 mg [22, 32]. MVC plasma exposures with the 
150 mg once-daily dose in MIDAS were also similar to levels achieved with the approved 
300 mg twice-daily dose when administered in the absence of potent CYP3A4 inhibitors 
and/or inducers [33]. Given potential differences in virologic suppression provided by 
DRV/r versus lamivudine/zidovudine, it is possible that MVC Ctrough and Cavg that correlate 
with virologic success with MVC/DRV/r may differ from the levels identified in MERIT 
(MVC plus lamivudine/zidovudine), but our study was not designed to address this. All but 
two participants in our study had VL < 50 copies/mL at week 48. All MVC concentrations 
were quantifiable, indicating that all subjects were taking MVC at the time of plasma 
sampling. The DHHS suggests a minimum trough concentration of 50 ng/mL in treatment-
experienced patients with VF [5].
By comparing virus decay during MVC/DRV/r treatment to previously reported decay rates 
with EFV- and LPV-containing regimens, we found that phase 1 decay (i.e., virus decay in 
the first 10 days of treatment) with MVC/DRV/r was faster than LPV plus two NRTIs and 
comparable to EFV plus two NRTIs [28, 29] and EFV plus LPV [28]. This is important 
because phase 1 virus decay rate, which reflects turnover of short-lived infected cells [34], 
correlates with subsequent virologic response [35], and can inform which experimental 
regimens merit further evaluation [28]. EFV-containing regimens have demonstrated faster 
phase 1 decay than LPV plus two NRTIs [28] and triple nucleoside ART [29]. In contrast to 
phase 1 decay, phase 2 decay rate reflects turnover of long-lived infected cells [34]. In our 
model, phase 2 decay was slower with MVC/DRV/r than EFV and LPV-containing 
regimens previously reported. One potential explanation for this is that ARV agents that act 
prior to viral integration such as EFV and MVC may increase the proportion of infected 
cells with longer half-life and thereby lower the apparent rate of phase 2 decay [28]. Indeed 
EFV has slower phase 2 decay than LPV, which acts after integration [28]. Overall, the virus 
decay pattern of MVC/DRV/r bears similarities with EFV-containing regimens, suggesting 
potent inhibition of infectious virion production.
Although the small number of participants and the single-arm design are limitations of our 
study, we have generated important virologic and PK data on MVC/DRV/r. Our ability to 
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characterize emergent resistance during VF was limited by occurrence of very few virologic 
failures and the low level of viremia in most of those who did. Another limitation of our 
study is that few participants had advanced HIV infection (median CD4 count at entry was 
455 cells/mm3, and those with CD4 <100 cells/mm3 were excluded). Therefore, our results 
may not apply to patients with very low CD4 counts. Finally, of the four participants with 
baseline VL >100,000 copies/mL in the study, two had VF at week 48 though one of them 
achieved viral suppression at week 84 on MVC/DRV/r. This is in contrast to a single VF 
among 20 subjects with VL < 100,000 copies/mL at baseline. While these are interesting 
observations, the small size of this study limits our ability to rigorously compare virologic 
responses in the different baseline VL strata. The small number of patients enrolled in this 
study and the variable blood sampling time limit the possibility to draw definitive 
conclusions on the potential association (or lack of association) between virologic outcome 
and MVC pharmacokinetics.
In conclusion, results of the MIDAS study support further evaluation of MVC/DRV/r 
150/800/100 mg once-daily for initial treatment of R5 HIV-1. A large multicenter clinical 
trial (MODERN) is already underway [NCT01345630]. MODERN and other future studies 
should determine the virologic efficacy of MVC/DRV/r across baseline VL strata, and 
characterize the resistance consequences of VF in patients receiving MVC/DRV/r, the 
pharmacokinetic correlates of virologic success, and the impact of NRTI-sparing on 
metabolic complications associated with HIV and contemporary antiretroviral therapy.
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Bi-exponential VL decay curves in the MIDAS study and two different ACTG clinical trials 
with NRTI-sparing arms. Using primary data from two AIDS Clinical Trials Group studies: 
EFV plus LPV/r, LPV/r plus 2NRTIs and EFV plus 2NRTIs in A5160s [28] and EFV plus 
2NRTIs in A5166s [29]
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MVC concentration-time data in 24 subjects receiving 150 mg once-daily with DRV/r 
800/100 mg once-daily. Solid line is the median simulated curve and dashed lines represent 
the 95th percentile confidence interval
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